Generic Eucrisa Availability
Last updated on May 7, 2025.
Eucrisa is a brand name of crisaborole topical, approved by the FDA in the following formulation(s):
EUCRISA (crisaborole - ointment;topical)
-
Manufacturer: ANACOR PHARMS INC
Approval date: December 14, 2016
Strength(s): 2% [RLD]
Is there a generic version of Eucrisa available?
No. There is currently no therapeutically equivalent version of Eucrisa available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Eucrisa. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Boron-containing small molecules
Patent 8,039,451
Issued: October 18, 2011
Inventor(s): Baker; Stephen J. et al.
Assignee(s): Anacor Pharmaceuticals, Inc. (Palo Alto, CA)This invention relates to compounds useful for treating fungal infections, more specifically topical treatment of onychomycosis and/or cutaneous fungal infections. This invention is directed to compounds that are active against fungi and have properties that allow the compound, when placed in contact with a patient, to reach the particular part of the skin, nail, hair, claw or hoof infected by the fungus. In particular the present compounds have physiochemical properties that facilitate penetration of the nail plate.
Patent expiration dates:
- June 29, 2029✓✓
- June 29, 2029
-
Boron-containing small molecules
Patent 8039451*PED
Issued: October 18, 2011
Inventor(s): Baker; Stephen J. et al.
Assignee(s): Anacor Pharmaceuticals, Inc. (Palo Alto, CA)This invention relates to compounds useful for treating fungal infections, more specifically topical treatment of onychomycosis and/or cutaneous fungal infections. This invention is directed to compounds that are active against fungi and have properties that allow the compound, when placed in contact with a patient, to reach the particular part of the skin, nail, hair, claw or hoof infected by the fungus. In particular the present compounds have physiochemical properties that facilitate penetration of the nail plate.
Patent expiration dates:
- December 29, 2029✓
- December 29, 2029
-
Boron-containing small molecules as anti-inflammatory agents
Patent 8,168,614
Issued: May 1, 2012
Inventor(s): Baker Stephen J. & Sanders Virginia & Akama Tsutomu & Bellinger-Kawahara Carolyn & Freund Yvonne & Maples Kirk R. & Plattner Jacob J. & Zhang Yong-Kang & Zhou Huchen & Hernandez Vincent S.
Assignee(s): Anacor Pharmaceuticals, Inc.Methods of treating anti-inflammatory conditions through the use of boron-containing small molecules are disclosed.
Patent expiration dates:
- January 20, 2030✓
- January 20, 2030
-
Boron-containing small molecules as anti-inflammatory agents
Patent 8168614*PED
Issued: May 1, 2012
Inventor(s): Baker Stephen J. & Sanders Virginia & Akama Tsutomu & Bellinger-Kawahara Carolyn & Freund Yvonne & Maples Kirk R. & Plattner Jacob J. & Zhang Yong-Kang & Zhou Huchen & Hernandez Vincent S.
Assignee(s): Anacor Pharmaceuticals, Inc.Methods of treating anti-inflammatory conditions through the use of boron-containing small molecules are disclosed.
Patent expiration dates:
- July 20, 2030✓
- July 20, 2030
-
Boron-containing small molecules as anti-inflammatory agents
Patent 8,501,712
Issued: August 6, 2013
Inventor(s): Baker Stephen J. & Sanders Virginia & Akama Tsutomu & Bellinger-Kawahara Carolyn & Freund Yvonne & Maples Kirk R. & Plattner Jacob J. & Zhang Yong-Kang & Zhou Huchen & Hernandez Vincent S.
Assignee(s): Anacor Pharmaceuticals, Inc.Methods of treating anti-inflammatory conditions through the use of boron-containing small molecules are disclosed.
Patent expiration dates:
- February 16, 2027✓
- February 16, 2027
-
Boron-containing small molecules as anti-inflammatory agents
Patent 8501712*PED
Issued: August 6, 2013
Inventor(s): Baker Stephen J. & Sanders Virginia & Akama Tsutomu & Bellinger-Kawahara Carolyn & Freund Yvonne & Maples Kirk R. & Plattner Jacob J. & Zhang Yong-Kang & Zhou Huchen & Hernandez Vincent S.
Assignee(s): Anacor Pharmaceuticals, Inc.Methods of treating anti-inflammatory conditions through the use of boron-containing small molecules are disclosed.
Patent expiration dates:
- August 16, 2027✓
- August 16, 2027
-
Boron-containing small molecules as anti-inflammatory agents
Patent 9,682,092
Issued: June 20, 2017
Inventor(s): Baker Stephen J. & Sanders Virginia & Akama Tsutomu & Bellinger-Kawahara Carolyn & Freund Yvonne & Maples Kirk R. & Plattner Jacob J. & Zhang Yong-Kang & Zhou Huchen & Hernandez Vincent S.
Assignee(s): Anacor Pharmaceuticals, Inc.Methods of treating anti-inflammatory conditions through the use of boron-containing small molecules are disclosed.
Patent expiration dates:
- February 16, 2027✓
- February 16, 2027
-
Boron-containing small molecules as anti-inflammatory agents
Patent 9682092*PED
Issued: June 20, 2017
Inventor(s): Baker Stephen J. & Sanders Virginia & Akama Tsutomu & Bellinger-Kawahara Carolyn & Freund Yvonne & Maples Kirk R. & Plattner Jacob J. & Zhang Yong-Kang & Zhou Huchen & Hernandez Vincent S.
Assignee(s): Anacor Pharmaceuticals, Inc.Methods of treating anti-inflammatory conditions through the use of boron-containing small molecules are disclosed.
Patent expiration dates:
- August 16, 2027✓
- August 16, 2027
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- April 3, 2026 - ADDITION OF A ONCE DAILY DOSING REGIMEN
More about Eucrisa (crisaborole topical)
- Compare alternatives
- Pricing & coupons
- Reviews (284)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: miscellaneous topical agents
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
